Literature DB >> 17503251

Supratherapeutic doses of sulfonylureas in diabetic patients: how much is too much?

F Lee Cantrell1, Richard F Clark.   

Abstract

BACKGROUND: Determining triage guidelines for supratherapeutic ingestions of sulfonylureas is difficult because they have broad therapeutic indexes. This study was performed to evaluate the degree of hypoglycemia that may result from a supratherapeutic ingestion of a sulfonylurea in a diabetic patient.
METHODS: Poison center records over a 3-year period were retrospectively reviewed for cases of adults acutely ingesting supratherapeutic doses of sulfonylureas (SFU).
RESULTS: A total of 85 cases were identified. Eight patients had complaints of shakiness or dizziness, but no patient developed symptoms refractory to oral glucose/carbohydrate supplementation or required intravenous dextrose.
CONCLUSIONS: In our study, all diabetic patients accidentally ingesting more than their usual single dose (USD) or usual daily dose (UDD) of their SFU were safely monitored at home while observing for subjective or objective signs of hypoglycemia. When necessary, oral dextrose could be administered in these patients at home.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503251     DOI: 10.1080/15563650701338203

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  1 in total

Review 1.  Treatment of sulfonylurea and insulin overdose.

Authors:  Wendy Klein-Schwartz; Gina L Stassinos; Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2016-01-06       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.